#ADA2025 featured posters from the ABCD audit programme: ow.ly/iUW250WpM3w
Dr Bob Ryder - ABCD EndoBarrier Worldwide Registry
Dr Alex Liarakos - ABCD NHS England Nationwide HCL Pilot Audit
Dr Kyaw Linn Su Khin - ABCD Nationwide Semaglutide Audit and Oral Semaglutide Audit

Take a look back at some past Templates. ⏪⏪ #tbt #DisabilityPrideMonth #DisabilityPride #ADA! #ADA2025 #DisabilityPride2025

Take a look back at some past Council Activities. ⏪⏪ #tbt #DisabilityPrideMonth #DisabilityPride #ADA! #ADA2025 #DisabilityPride2025

Take a look back at some past Testimonies/Legislative Advocacy. ⏪⏪ #tbt #DisabilityPrideMonth #DisabilityPride #ADA! #ADA2025 #DisabilityPride2025

#ADA2025 featured posters from the ABCD audit programme: abcd.care/announcement...
▶️ Dr Bob Ryder - ABCD EndoBarrier Worldwide Registry
▶️ Dr Alex Liarakos - ABCD NHS England Nationwide HCL Pilot Audit
▶️ Dr Kyaw Linn Su Khin - ABCD Nationwide Semaglutide Audit and Oral Semaglutide Audit

Take a look back at some past ADA events. ⏪⏪ #tbt #DisabilityPrideMonth #DisabilityPride #ADA! #ADA2025 #DisabilityPride2025

Lean Diabetes: A Diagnosis of Exclusion Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, or other diabetes types before confirming the diagnosis.

Story from #ADA2025: I used to think that a lean person couldn't have #type2diabetes and in fact, many are misdiagnosed and actually have #type1diabetes or #MODY. But, "lean type 2" does exist, proving how much is still to be learned about #diabetes : www.medscape.com/viewarticle/...

Weekly fixed-dose basal insulin noninferior to glargine for type 2 diabetes control Once-weekly, fixed-dose insulin efsitora has been found noninferior to insulin glargine at reducing glycated hemoglobin levels in people with type 2 diabetes.

From #ADA2025 - Once-weekly, fixed-dose insulin #efsitora has been found noninferior to insulin #glargine at reducing glycated hemoglobin levels in people with #T2D.

Full story 👉 buff.ly/xjwKO77

#MedNews #Insulin

American Diabetes Association Archives Presenting research from the annual meeting of the American Diabetes Association.

Looking to catch up on research from #ADASciSessions? Check out Endocrinology Advisor's coverage below ⬇️
#ADA2025 #EndoSky #MedSky @amdiabetesassn.bsky.social

Zimislecel promotes islet cell rejuvenation in type 1 diabetes The stem cell therapy zimislecel reduces the need for exogenous insulin treatments and restores islet function in patients with type 1 diabetes.

From #ADA2025 - The stem cell therapy #zimislecel reduces the need for exogenous insulin treatments and restores islet function in patients with #T1D.

Full story 👉 buff.ly/rK9Lopn

#DiabetesSky #MedSky

8⃣ #ADA2025 84.ªs Sesiones Científicas de
@AmDiabetesAssn
⭕️Over‑the‑Counter Continuous #GlucoseMonitoring-Data for All or a Disaster Waiting to Happen?
⭕️Monitorización continua de glucosa sin receta: ¿datos para todos o un desastre inminente?

redgedaps.blogspot.com/2025/07/ada202…i

Phase 2 study demonstrates weight loss potential of maridebart cafraglutide The long-acting peptide–antibody conjugate maridebart cafraglutide significantly reduces bodyweight versus placebo in people with obesity with or without type 2 diabetes.

From #ADA2025 - The long-acting peptide–antibody conjugate maridebart cafraglutide significantly reduces bodyweight versus placebo in people with obesity with or without #T2D.

Full story 👉 buff.ly/mtNnrA8

#Diabetes #MedNews

“If you treat someone’s blood pressure or cholesterol you don’t get improvements in quality of life. You treat their weight you get all the benefits."

"That is the power of treating obesity.”

Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025

Check out #dkNET community news, events and #funding announcements in July 2025! dknet.org/about/blog/2...
#bioinformatics #endocrinology #diabetes #FAIRdata #webinar #datascience #T1D #ADASciSessions #ADA2025 #T2D #SummerProgram

7️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn

⭕️ Simposio sobre el papel de la #IA en la mejora de las recomendaciones de INS y los resultados de la terapia

Comentario de Enrique Carretero Anibarro (@Enriq_Carretero)

redgedaps.blogspot.com/2025/07/ada-20…

6️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn.

⁉️Si tuvieras que elegir solo 1 fármaco para la #DM2?
Debate -If You Had to Pick Just One—GLP-1RA, GIP/GLP-1RA or SGLT2i for Type 2 Diabetes?
Comentario del Dr. Javier Díez Espino (@DiezEspino)

redgedaps.blogspot.com/2025/07/ada-20…

5️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn.

Interesantísimo simposio de la Revista Lancet: #DM2 de inicio temprano (DM2-IT)

Comentario del Dr. Joan Barrot de la Puente (@JoanBarrot)

👇
redgedaps.blogspot.com/2025/07/ada-20…

4️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn.

Simpo "Diabetes y enfermedad arterial periférica (EAP): papel evolutivo del agonista del receptor GLP-1 y nuevos hallazgos del ensayo STRIDE".

Comentado en #BlogDeMateu por @maruizquintero:

🔗 redgedaps.blogspot.com/2025/06/ada-20…

3️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn
Simposio: Eficacia y seguridad de CagriSema 2,4 mg/2,4 mg en adultos con sobrepeso/obesidad: ensayos clínicos REDEFINE 1 y REDEFINE 2
Comentario del Dr. Manuel Ruiz Quintero (@maruizquintero)
👇🏼
redgedaps.blogspot.com/2025/06/ada-20…

#TBT to a past campaign for ADA Awareness on July 13th, 2018! Celebrating on Point Pleasant, getting signatures for the Erase the 'R' Word pledge, giving out prizes, and educating people about the #ADA! #ADA2025 #DisabilityPride2025

DT1 : les îlots pancréatiques dérivés de cellules souches continuent de produire de l'insuline après un an Des données à un an suggèrent que la thérapie à base de cellules d'îlots pancréatiques dérivées de cellules souches allogéniques pourrait devenir une option d'avenir pour les patients diabétiques de type 1 chez lesquels les avantages l'emportent sur les risques liés à l'immunosuppression.

DT1 : les îlots pancréatiques dérivés de cellules souches continuent de produire de l'insuline après un an #ADA2025
http://ms.spr.ly/63321S2X7F

Most T1D Patients Insulin-Free After Stem Cell Infusion, Small Trial Reports All participants achieved an HbA1c under 7%

"If you define functional cure by accepting the requirement for immunosuppression, then I think you could call [this] a functional cure." -- Michael Rickels, MD, on a stem cell therapy that helped people with #T1D achieve insulin independence. #ADA2025
www.medpagetoday.com/meetingcover...

CagriSema may REDEFINE weight loss treatment Combination treatment with cagrilintide and semaglutide significantly reduces bodyweight in adults living with overweight or obesity, with or without type 2 diabetes.

From #ADA2025 - Combination treatment with #cagrilintide and #semaglutide significantly reduces bodyweight in adults living with overweight or #obesity, with or without type 2 #diabetes.

Full story 👇
buff.ly/eIVl1fx

Richard Anderson | Facebook | Linktree View RichardAnderson’s Linktree to discover and stream music from top platforms like YouTube, Spotify, Apple Music here. Your next favorite track is just a click away!

🎶 I may not sing like most folks—but I do drop country music with heart, twang, and tech.

Speech impairment? Yep.
Love for real country music? Bigger than Oklahoma's heart.

🎧 Crank it up here: linktr.ee/RichardAnder...

#thatlonesomewind #RichardAnderson #ADA2025 #aiartist #NowPlaying

On this day in 1990, President George H.W. Bush signed the landmark disability rights law known as the Americans with Disabilities Act (ADA). The ADA turns 35 today, and we remain committed to fulfilling Justin Dart, Jr.'s dream! 🧑‍🦼👩‍🦽👨‍🦯🦾🦮🐕‍🦺♿️ #ada2025 #ThanksToTheADA #ada35 #ADAanniversary

Such a flood of #innovation in #ObesityMedicines this week at #ADA2025 that investors are struggling to follow the thread and remember that obesity is a chronic disease. It's a marathon, not a sprint.
conscienhealth.org/2025/06/look...

ADA Roundup: Weight-Loss Studies Take Center Stage More highlights from the American Diabetes Association annual meeting

Missed #ADA2025? We've got you covered.

Read the full round up: www.medpagetoday.com/meetingcover...

Amycretin shows promise in early trials among people with overweight, obesity The single-molecule, dual GLP-1 and amylin receptor agonist amycretin shows promising tolerability and weight loss when given orally or subcutaneously to adults with overweight or obesity.

From #ADA2025 - The single-molecule, dual GLP-1 and amylin receptor agonist #amycretin shows promising tolerability and weight loss when given orally or subcutaneously to adults with overweight or #obesity.

Full story 👉 buff.ly/xrEqw3N

#MedSky #MedNews #GLP1

Catch up on the latest breakthroughs in #diabetes research from the #ADA2025 Annual Meeting with our hub page.

Access the hub for free here 👉 buff.ly/hNpwEZv

#DiabetesSky #EndoSky #MedNews

2️⃣ #ADA2025 84.ªs Sesiones Científicas de @AmDiabetesAssn

Lo pequeño puede ser grande Symposium. Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?

Comentario del Dr.Javier Díez Espino (@DiezEspino)

redgedaps.blogspot.com/2025/06/ada-20…

Te lo contamos 👇